Instituto de Medicina Integral Professor Fernando Figueira   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Recife Brazil (1960)

Organization Overview

First Clinical Trial
2006
NCT00288600
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Fernando Figueira IMIP | Fernando Fiqueira IMI | Flávia A de Orange, PhD | Hospital de Figueres | IMIP | Instituto de Medicina Integral Professor Fernando Figueira | Instituto de Medicina Integral Prof Fernando Figueira | Instituto de Medicina Integral Prof. Fernando Figueira | Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) | Instituto Fernandes Figueira | Instituto Materno Infantil Prof. Fernando Figueira | Professor Fernando Figueira Integral Medicine Institute

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Avitaminosis (Phase 3)

Blood Loss, Surgical (Phase 4)

Calcinosis (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Catheter-Related Infections (Phase 3)

Cleft Palate (Phase 4)

Cognition Disorders (Phase 4)

Cognitive Dysfunction (Phase 4)

Communicable Diseases (Phase 3)

Delirium (Phase 4)

Eclampsia (Phase 4)

Erythroblastosis, Fetal (Phase 4)

HELLP Syndrome (Phase 4)

Hemorrhage (Phase 4)

HIV Infections (Phase 4)

Hyperbilirubinemia (Phase 4)

Hypertension (Phase 4)

Hypotension (Phase 3)

Infections (Phase 3)

Inflammation (Phase 4)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Leprosy (Phase 3)

Leukemia (Phase 3)

Magnesium Deficiency (Phase 3)

Night Blindness (Phase 3)

Ovarian Neoplasms (Phase 2)

Postoperative Nausea and Vomiting (Phase 3)

Pre-Eclampsia (Phase 4)

Premature Birth (Phase 3)

Psychomotor Agitation (Phase 3)

Syndrome (Phase 4)

Toxemia (Phase 3)

Uterine Cervical Incompetence (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Vascular Calcification (Phase 3)

Vitamin A Deficiency (Phase 3)

Vomiting (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 29
  • # of Trial APIs: 33